Creation of a constitutively activated state of the 5-hydroxytryptamine (2A) receptor by site-directed mutagenesis: Inverse agonist activity of antipsychotic drugs

Journal of Pharmacology and Experimental Therapeutics

Volumn 286, Issue 1, 1998, Pages 85-90

  Egan, Christina T ^a   Herrick Davis, Katharine ^a   Teitler, Milt ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,5 DIMETHOXY 4 METHYLAMPHETAMINE; AMPHETAMINE DERIVATIVE; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; KETANSERIN; LOXAPINE; METHYSERGIDE; MIANSERIN; NEUROLEPTIC AGENT; RISPERIDONE; SEROTONIN; SEROTONIN 2A AGONIST; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; SPIPERONE;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ISOTOPE LABELING; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; SEROTONINERGIC SYSTEM; SITE DIRECTED MUTAGENESIS;

ANIMALS; ANTIPSYCHOTIC AGENTS; COS CELLS; MUTAGENESIS, SITE-DIRECTED; PHOSPHATIDYLINOSITOLS; PROTEIN CONFORMATION; RATS; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, SEROTONIN; SEROTONIN; SEROTONIN AGONISTS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0031846352     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Barker EL, Westphal RS, Schmidt D and Sanders-Bush E (1994) Constitutively active 5-hydroxytryptamine receptors reveal novel inverse agonist activity of receptor liganda. J Biol Chem 269:11687-11690.
2. Burstein ES, Spalding TA, Hill-Eubanks D and Brann MR (1995) Structure/function of muscarinic receptor to G proteins: Random-saturation mutagenesia identifies a critical determinant of receptor affinity for G proteins. J Biol Chem 270:3141-3146.
3. Conn PJ and Sanders-Bush E (1984) Selective 5HT-2 antagonists inhibit serotonin stimulated phosphatidylinositol metabolism in cerebral cortex. Neuropharmacology 23:993-996.
4. 1-adrenergic receptor involved in coupling to phosphatidylinositol hydrolysis and enhanced sensitivity of biological function. Proc Natl Acad Sci USA 87:2896-2900.
5. 1B-adrenergic receptor determine selectivity of coupling to phosphatidyl-inositol hydrolysis. J Biol Chem 267:1633-1639.
6. Cowen PJ (1991) Serotonin receptor subtypes: implications for psychopharmacology. Br J Psychiatry 159:7-14.
7. de Courcelles D, Leysen J, DeClerck F, Van Belle H and Janssen P (1985) Evidence that phospholipid turnover is the signal transducing system coupled to serotonin-S2 receptor sites. J Biol Chem 260:7603-7608.
8. 1A angiotensin II receptor induces its constitutive activation. J Biol Chem 272:1822-1826.
9. Hamdorf K and Kirschfeld K (1980) Reversible events in the transduction process of photoreceptors. Nature 283:859-860.
10. Hasegawa H, Negishi M and Ichikawa A (1996) Two isoforms of the prostaglandin E receptor EP3 subtype differ in agonist-independent constitutive activity. J Biol Chem 271:1857-1860.
11. 2C receptor. J Neurochem 69:1138-1144.
12. Kane J, Honigfeld G, Singer J and Meltzer HY (1988): Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789-796.
13. Kenakin T (1995) Agonist-receptor efficacy. II. Agonist-trafficking of receptor signals. Trends Pharmacol Sci 16:232-238.
14. IB receptor by all amino acid substitutions at a single site. J Biol Chem 267:1430-1433.
15. i values. J Pharmacol Exp Ther 251:238-246.
16. Meltzer HY and Nash JF (1991) Effects of antipsychotic drugs on serotonin receptors. Pharmacol Rev 43:587-604.
17. Meltzer HY (1995) Clozapine: is another view valid? Am J Psychiatry 152.821-825.
18. Nanevicz T, Wang L, Chen M, Iahii M and Coughlin SR (1996) Thrombin receptor activating mutations. J Biol Chem 271:702-706.
19. Parma J, Duprez L, VanSande J, Cochaux P, Gervy C, Mockel J, Dumont J and Vassart G (1993) Somatic mutations in the thyrotropin gene cause hyperfunctioning thyroid adenomas. Nature 365:649-651.
20. Rao VR, Cohen GB and Oprian DD (1994) Rhodopsin mutation G90D and a molecular mechanism for congenital night blindness. Nature 367:639-642.
21. 2-adrenergic receptor. J Biol Chem 268:16483-16487.
22. Robbins LS, Nadeau JH, Johnson KR, Kelly MA, Roselli-Rehfuss L, Baack E, Mountjoy KG and Cone RD (1993) Pigmentation phenotypes of variant extension locus alleles result from point mutations that alter MSH receptor function. Cell 72:827-834.
23. 2-adrenergic receptor. J Biol Chem 268:4625-4636.
24. Schipani E, Kruse K and Jueppner HA (1995) Constitutively active mutant PTH-PTHrP receptor in Jansen-type metaphyseal chondrodysplasia. Science 268:98-102.
25. Shenker A, Laue L, Kosugi S, Meredino JJ Jr, Minegishi T and Cutler GB Jr (1993) A constitutively activating mutation of the luteinizing hormone receptor in familial male precocious puberty. Nature 366:652-654.
26. Soejima M and Noma A (1984) Mode of regulation of the Ach-sensitive K-channel by the muscarinic receptor in rabbit atrial cells. Pflugers Arch 400:424-431.
27. Spalding TA, Burstein ES, Brauner-Osborne H, Hill-Eubanks D and Brann ME (1995) Pharmacology of a constitutively active muscarinic receptor generated by random mutagenesis. J Pharmacol Exp Ther 275:1274-1279.
28. Strader CD, Dixon RIF, Cheung AH, Candelore MR, Blake AD, Sigal IS (1987) Mutations that uncouple the β-adrenerigc receptor from Gs and increase agonist potency. J Biol Chem 262:16439-16443.
29. 2 receptor subtypes. Mol Pharmacol 38:594-598.
30. 1B receptor subtype. J Biol Chem 269:27295-27931.
31. Wong SKF, Parker EM, Ross EM (1990) Chimeric muscarinic cholinergic: β-adrenergic receptors that activate Gs in response to muscarinic agonists. J Biol Chem 265:6219-6224.